<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04079426</url>
  </required_header>
  <id_info>
    <org_study_id>BOST-002</org_study_id>
    <nct_id>NCT04079426</nct_id>
  </id_info>
  <brief_title>Tetracycline to Limit the Innate Immune Response in Acute Respiratory Distress Syndrome</brief_title>
  <official_title>Innate Immunity in Acute Respiratory Distress Syndrome: A Translational Approach to Limit Inflammasome-dependent Lung Inflammation by Tetracycline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The acute respiratory distress syndrome (ARDS) is a severe form of respiratory failure with a
      mortality rate of approximately 40%. Despite advances in its supportive treatment such as
      lung protective ventilation or restrictive fluid management, no effective pharmacotherapy
      exists to treat ARDS. Emerging preclinical data indicates that excessive activation of the
      inflammasome-Caspase 1 pathway plays a key role in the development of ARDS. Tetracycline has
      anti-inflammatory properties via inhibiting inflammasome-caspase-1 activation. Since not much
      is known about the activation of the inflammasome in clinical ARDS, the purpose of this study
      is i) to investigate the the inflammasome-caspase-1 activation in clinical ARDS and ii)
      inhibit the innate immune response of alveolar leucocytes obtained by tetracycline from
      patients with ARDS
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine Levels in Serum and bronchoalveolar fluid</measure>
    <time_frame>1 week</time_frame>
    <description>determined by multiplex Assay [pg/ml]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Activation Status of immune cells from blood and bronchoalveolar fluid</measure>
    <time_frame>1 week</time_frame>
    <description>incubation of immune cells with tetracycline and Determination of cytokines by multiplex assay [pg/ml]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alarmins in Serum and bronchoalveolar fluid</measure>
    <time_frame>1 week</time_frame>
    <description>Determination by western blot, qPCR or flow cytometry</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Adult Respiratory Distress Syndrome</condition>
  <condition>Pneumonia</condition>
  <condition>Sepsis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sampling of Blood and bronchoalveolar lavage</intervention_name>
    <description>Multiplex assays for pro- and anti-inflammatory markers and incubation of immune cells isolated from serum and bronchoalveolar lavage fluid of patients with ARDS.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants admitted to the Intensive Care Unit of the University Hospital of Bonn with an
        initial diagnosis of ARDS
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Informed consent of the patient

          -  Diagnosis of ARDS for &lt; 48 h

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Missing informed consent

          -  Immune therapy

          -  Autoimmune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christian Bode, Dr</last_name>
    <phone>+49228287</phone>
    <phone_ext>14119</phone_ext>
    <email>christian.bode@ukbonn.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chrisitan Bode, MD</last_name>
      <phone>+4922828714119</phone>
      <email>christian.bode@ukb.uni-bonn.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bonn</investigator_affiliation>
    <investigator_full_name>Dr. Christian Bode</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>inflammasome</keyword>
  <keyword>Caspase</keyword>
  <keyword>NLRP3</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>Tetracycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

